

REMARKS

The preliminary amendment presented above is submitted to correct certain typographical errors without introducing new matter that goes beyond the disclosure in the specification as originally filed.

The specification has been amended at pages 59, 116 and 117-118 to correct an error in the assignment of sequence identifiers. The sequence indicated as "SEQ ID NO:Y" at page 118, lines 4 in the specification as originally filed was included as SEQ ID NO:135 in the original Sequence Listing. The sequence designated as SEQ ID NO:135 at page 188, line 3 of the specification as originally filed was included in the original Sequence Listing as SEQ ID NO:134. In the amendment presented above, the paragraph spanning pages 117-118 of the specification has been amended to replace SEQ ID NO:135 with SEQ ID NO:134 and to replace SEQ ID NO:Y with SEQ ID NO:135. The sequence at pages 59 and 116 that was originally designated as SEQ ID NO:134 (and omitted from the original Sequence Listing), has now been designated at SEQ ID NO:187.

A substitute Sequence Listing is submitted herewith in both paper and computer-readable formats to incorporate SEQ ID NO:187.

A replacement sheet with a revised Figure 30C is submitted herewith to remove an extraneous symbol that appeared in line 3361 in Figure 30C as originally filed (the extraneous symbol is inserted where nucleotide 3363 should be).

A replacement sheet with a revised Figure 30D is submitted to correct the indicated sequence identifiers from SEQ ID NO:183 and SEQ ID NO:184 to SEQ ID NO:185 and SEQ ID NO:186.

Applicants submit that these amendments present no new matter that goes beyond the specification as originally filed and request entry thereof.

This application is now in condition for substantive examination, which action is respectfully requested.

Respectfully submitted,


Karen A. Magri
Registration No. 41,965